Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509694 | 0.89 | LMNA (0.30) | TSHRLMNA | |
| SCHEMBL1680269 | 0.87 | TSHR (0.42) | TSHRTHRB | |
| SCHEMBL1680605 | 0.87 | TSHR (0.32) | TSHR | |
| SCHEMBL17819275 | 0.85 | — | — | |
| SCHEMBL17781255 | 0.85 | TSHR (0.33) | TSHR | |
| SCHEMBL692705 | 0.83 | — | — | |
| SCHEMBL6697084 | 0.83 | ALDH1A1 (0.33) | TSHRTHRB | |
| SCHEMBL31515197 | 0.81 | TSHR (0.54) | TSHRLMNATHRB | |
| SCHEMBL3146855 | 0.81 | L3MBTL1 (0.31) | — | |
| SCHEMBL20165967 | 0.81 | DNM1 (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4548937-A1 | ANTIBODY-DRUG COMPLEX | Eisai R&D Management Co., Ltd. (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-05-09 | — | — | US | disclosed |
| US-20240083908-A1 | TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS | ALIVEXIS, INC. (JP) | 2024-03-14 | — | — | US | disclosed |
| WO-2024043319-A1 | ANTIBODY-DRUG COMPLEX | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2024-02-29 | — | — | WO | disclosed |
| EP-4269415-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | Modulus Discovery, Inc. (JP) | 2023-11-01 | — | — | EP | disclosed |
| CN-116583286-A | Tetrahydrothienopyrimidine sulfonamide compounds | 某久拉斯株式会社 | 2023-08-11 | — | — | CN | disclosed |
| CN-115448916-A | TYK2 inhibitor and application thereof | 林伯士拉克许米公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-109952303-B | TYK2 inhibitor and application thereof | 林伯士拉克许米公司 | 2022-10-21 | — | — | CN | disclosed |
| WO-2022138812-A1 | TETRAHYDRO THIENOPYRIDINE SULFONAMIDE COMPOUND | モジュラス株式会社 | 2022-06-30 | — | — | WO | disclosed |
| US-9975910-B2 | Hetero-fused cyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-20160168176-A1 | HETERO-FUSED CYCLIC COMPOUND | Eisai R&D Management Co., Lt.d (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-3026054-A1 | HETERO-CONDENSED RING COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2016-06-01 | — | — | EP | disclosed |
| WO-2012088402-A1 | SYNTHESIS OF CONOLIDINE AND DISCOVERY OF A POTENT NON-OPIOID ANALGESIC FOR PAIN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20080280836-A1 | Anti-hypercholesterolemic biaryl azetidinone compounds | MORRIELLO GREGORI J | 2008-11-13 | — | — | US | disclosed |
| US-20080261923-A1 | Alkene Mimics | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-23 | — | — | US | disclosed |
| WO-2006020417-A2 | ALKENE MIMICS | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-5134128-A | Immunosuppressive and antiproliferative activity for psoriasis and calcium homeostasis | ALLERGAN, INC. (US) | 1992-07-28 | — | — | US | disclosed |
| EP-0372941-A2 | Anti-inflammatory 5-hydroxy-2-furanones | ALLERGAN, INC (US) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083908-A1 | TETRAHYDROTHIENOPYRIMIDINESULFONAMIDE COMPOUNDS | TYMS, TYMP, TPMT | TSHR 2507/4885LMNA 1435/4885THRB 2014/4885 |
| US-20080280836-A1 | Anti-hypercholesterolemic biaryl azetidinone compounds | APOB, PCSK9, CYP46A1 | TSHR 4110/4885LMNA 1127/4885THRB 2093/4885 |
| US-20240148895-A1 | ANTIBODY-DRUG CONJUGATE | ANTXR2, FCGR1A, HAX1 | TSHR 2089/4885LMNA 2756/4885THRB 4038/4885 |
| US-20160168176-A1 | HETERO-FUSED CYCLIC COMPOUND | NR3C2, NR1H4, NR1I3 | TSHR 1103/4885LMNA 4163/4885THRB 910/4885 |
| US-20080261923-A1 | Alkene Mimics | PHOSPHO1, PARN, CHAMP1 | TSHR 3267/4885LMNA 1092/4885THRB 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.